Jesus Delgado-Calle, PhD

Research Program: Cancer Biology Faculty Rank: Associate Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Physiology & Cell Biology

Cancer Research Interest

• Research Interest Statement: My research focuses on understanding the mechanisms by which cancer myeloma (MM) cells alter the biology of other cells in the tumor/bone marrow microenvironment, in particular osteocytes, with the final goal of identifying targetable factors for the treatment of cancer that grows in bone. My expertise is on osteocyte biology and pathophysiology, with experience in ex vivo and in vitro models to study osteocyte-tumor biology, and characterization of tumor growth and bone remodeling in animal models of MM-induced bone disease using genetic and pharmacologic approaches. Current projects in my laboratory investigate the effects of osteocyte-derived factors (i.e. Sclerostin) and Notch signaling communication in the tumor niche on MM growth, disease relapse, and bone disease. I also maintain an international collaboration with PharmaMar (Spain) to test the effects of Aplidin, a novel anti-tumor drug, on bone cells and MM growth. Moreover, I collaborate in studies examining the role of osteocytes in cancer-induced bone pain and muscle weakness.

Contact Information

• Email Address: JDELGADOCALLE@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• NIH/Nat. Cancer Institute – 2R01CA209882
  “Contribution of osteocytes to the musculoskeletal effects of Multiple Myeloma”
  Principal Investigator
  07/01/23 – 06/30/28
• NIH/National Institutes of Health – R01CA241677
  “Osteoclast-Osteocyte Interaction's in Paget's Disease- Sub with Indiana University”
  Principal Investigator
  03/01/22 – 02/28/28
• NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases – 1R01AR080116
  “Osteoclast-Osteocyte Interaction's in Paget's Disease- Sub with Indiana University”
  Principal Investigator
  02/22/22 – 12/31/26
• NIH/Nat. Cancer Institute – 1R37CA251763
  “Bone-Targeted Therapies to Improve Bone Health and Prevent Relapse in Multiple Myeloma”
  Principal Investigator
  09/01/20 – 05/31/25
• NIH/Nat. Cancer Institute – 1R01CA241677
  “Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone Disease”
  Principal Investigator
  07/01/20 – 02/28/25

Publications

• Tenshin H, Delgado-Calle J, Windle JJ, [et al.]. Osteocytes and Paget's Disease of Bone. Current osteoporosis reports. 2024. PMID: 38457001.
• Sabol HM, Ashby C, Adhikari M, [et al., including Delgado-Calle J]. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024. PMID: 38385272.
• Marino S, Petrusca DN, Bishop RT, [et al., including Delgado-Calle J]. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma. Haematologica. 2023. PMID: 37981834.
• García-Sánchez D, González-González A, Álvarez-Iglesias I, [et al., including Delgado-Calle J]. Engineering a Pro-Osteogenic Secretome through the Transient Silencing of the Gene Encoding Secreted Frizzled Related Protein 1. International journal of molecular sciences. 2023 24(15). PMID: 37569774. PMCID: PMC10419110.
• Miyagawa K, Tenshin H, Mulcrone PL, [et al., including Delgado-Calle J]. Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to pagetic lesion formation. JCI insight. 2023 8(14). PMID: 37338990. PMCID: PMC10443794.
• Delgado-Calle J, Roodman GD. Doubling Down on Wnt Signaling to Overcome Myeloma Bone Disease. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2023 38(6):812-813. PMID: 37277117. PMCID: PMC10330486.
• Anloague A, Delgado-Calle J. Osteocytes: New Kids on the Block for Cancer in Bone Therapy. Cancers. 2023 15(9). PMID: 37174109. PMCID: PMC10177382.
• Schinke C, Weinhold N, Delgado-Calle J. Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy. Frontiers in oncology. 2023 13:1157555. PMID: 36895479. PMCID: PMC9990495.
• Wanchai V, Jenjaroenpun P, Leangapichart T, [et al., including Delgado-Calle J]. CReSIL: accurate identification of extrachromosomal circular DNA from long-read sequences. Briefings in bioinformatics. 2022. PMID: 36198068. PMCID: PMC10144670.
• Sabol HM, Amorim T, Ashby C, [et al., including Delgado-Calle J]. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia (New York, N.Y.). 2022 28:100785. PMID: 35390742. PMCID: PMC8990177.
• Delgado-Calle J, McAndrews K, Wu G, [et al.]. The Notch pathway regulates the bone gain induced by PTH anabolic signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2022 36(3):e22196. PMID: 35137455. PMCID: PMC8855690.
• Chen J, Cuevas PL, Dworan JS, [et al., including Delgado-Calle J]. Wnt/β-catenin Signaling Controls Maxillofacial Hyperostosis. Journal of dental research. 2022:220345211067705. PMID: 35114849. PMCID: PMC10850863.
• Sabol HM, Ferrari AJ, Adhikari M, [et al., including Delgado-Calle J]. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. Cancer research. 2021. PMID: 34348968. PMCID: PMC8488008.
• Delgado-Calle J, Bellido T. The osteocyte as a signaling cell. Physiological reviews. 2021. PMID: 34337974. PMCID: PMC8858675.
• Adhikari M, Delgado-Calle J. Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease. Current osteoporosis reports. 2021. PMID: 33818732. PMCID: PMC8486016.
• Sabol HM, Delgado-Calle J. The multifunctional role of Notch signaling in multiple myeloma. Journal of cancer metastasis and treatment. 2021 7. PMID: 34778567. PMCID: PMC8589324.
• Chen J, Yuan X, Pilawski I, [et al., including Delgado-Calle J]. Molecular Basis for Craniofacial Phenotypes Caused by Sclerostin Deletion. Journal of dental research. 2020:22034520963584. PMID: 33078679. PMCID: PMC7903846.
• Mulcrone PL, Edwards SKE, Petrusca DN, [et al., including Delgado-Calle J]. Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23. Scientific reports. 2020 10(1):17319. PMID: 33057033. PMCID: PMC7560700.
• Miyagawa K, Ohata Y, Delgado-Calle J, [et al.]. Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo. JCI insight. 2020 5(6). PMID: 32078587. PMCID: PMC7213785.
• Bellido T, Delgado-Calle J. Ex Vivo Organ Cultures as Models to Study Bone Biology. JBMR plus. 2020 4(3). PMID: 32161838. PMCID: PMC7059827.